Vimarsana
Biggest News Aggregation in the World

Page 49 - Early Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Early Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Early Access Program Today - Breaking & Trending Today

Eve rolling out Matter firmware update for some HomeKit products - Vimarsana News

Eve rolling out Matter firmware update for some HomeKit products

Eve has started the rollout of an optional firmware update to support Matter on Apple devices, but Homekit-only users aren't being left behind.

Eve rolling out Matter firmware update for some HomeKit products - General Discussion Discussions on AppleInsider Forums - Vimarsana News

Eve rolling out Matter firmware update for some HomeKit products - General Discussion Discussions on AppleInsider Forums

Eve has started the rollout of an optional firmware update to support Matter on Apple devices, but Homekit-only users aren't being left behind.

MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting - Vimarsana News

MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting

Oral presentation at 64th American Society of Hematology Annual Meeting includes promising results from 81 patients with steroid-resistant, gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) treated with MaaT013 as part of compassionate use program (Early Access Program or EAP) in France.Results showed a GI...

AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen (Rintatolimod) in Healthy Subjects - Vimarsana News

AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen (Rintatolimod) in Healthy Subjects

Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral

KemPharm Announces Appointment of Christopher Posner as New - Vimarsana News

KemPharm Announces Appointment of Christopher Posner as New

24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov. ...